MISSION

NBO (acronym for Nasal Bioavailability of Octreotide) Pharma Inc. was incorporated in 2021 to develop a drug for the treatment of Idiopathic Intracranial Hypertension [IIH] for which no drugs are approved. We are re-purposing an existing orphan drug – octreotide acetate – with an Intranasal [IN] formulation. IN octreotide is undergoing clinical trials for IIH.

IDIOPATHIC INTRACRANIAL HYPERTENSION

Untreated IIH can lead to papilledema [bilateral optic nerve swelling]; it can be progressive and lead to enlargement of blind spots, visual obscurations, and loss of vision.

OCTREOTIDE PROOF OF CONCEPT IN IIH PATIENTS

Six open label studies with injectable octreotide have shown the drug to be effective in lowering intracranial pressure [ICP], reducing headache, and improving visual symptoms when administered up to 3 times a day. Intranasal delivery aims to reduce the frequency of administration, enable the use of lower amounts of drug, lower systemic side effects, and avoid pain and discomfort associated with an injectable product.

MISSION

NBO (acronym for Nasal Bioavailability of Octreotide) Pharma Inc. was incorporated in 2021 to develop a drug for the treatment of Idiopathic Intracranial Hypertension [IIH] for which no drugs are approved. We are re-purposing an existing orphan drug – octreotide acetate – with an Intranasal [IN] formulation. IN octreotide is undergoing clinical trials for IIH.

IDIOPATHIC INTRACRANIAL HYPERTENSION

Untreated IIH can lead to papilledema [bilateral optic nerve swelling]; it can be progressive and lead to enlargement of blind spots, visual obscurations, and loss of vision.

OCTREOTIDE PROOF OF CONCEPT IN IIH PATIENTS

Six open label studies with injectable octreotide have shown the drug to be effective in lowering intracranial pressure [ICP], reducing headache, and improving visual symptoms when administered up to 3 times a day. Intranasal delivery aims to reduce the frequency of administration, enable the use of lower amounts of drug, lower systemic side effects, and avoid pain and discomfort associated with an injectable product.